Astria Therapeutics, Inc. (ATXS)
NASDAQ: ATXS · Real-Time Price · USD
12.62
+0.37 (3.02%)
Nov 5, 2025, 4:00 PM EST - Market closed
Astria Therapeutics Employees
Astria Therapeutics had 78 employees as of December 31, 2024. The number of employees increased by 19 or 32.20% compared to the previous year.
Employees
78
Change (1Y)
19
Growth (1Y)
32.20%
Revenue / Employee
n/a
Profits / Employee
-$1,498,987
Market Cap
712.21M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 78 | 19 | 32.20% |
| Dec 31, 2023 | 59 | 17 | 40.48% |
| Dec 31, 2022 | 42 | 13 | 44.83% |
| Dec 31, 2021 | 29 | 9 | 45.00% |
| Dec 31, 2020 | 20 | -7 | -25.93% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ATXS News
- 5 days ago - Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting - Business Wire
- 19 days ago - Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS - Business Wire
- 22 days ago - BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate' - Benzinga
- 22 days ago - BioCryst to buy Astria Therapeutics in $700 million deal - Reuters
- 22 days ago - BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile - Business Wire
- 27 days ago - Astria Therapeutics to Present at Upcoming CSACI 80th Anniversary Scientific Meeting - Business Wire
- 4 weeks ago - Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with Hereditary Angioedema - Business Wire
- 4 weeks ago - Astria Therapeutics to Present at Upcoming 2025 HAEi Regional Conference EMEA - Business Wire